Another potential opportunity for Leronlimab is to

Another potential opportunity for Leronlimab is to curb the cytokine release syndrome (CRS) associated with CaR-T therapies (cancer and HIV cure). An old but interesting article (March2020) discusses use of CaR-T for HIV and brief mention for blood cancers, and use of Tocilizumab (IL-6 inhibitor) and corticosteroids as mitigation for CRS. Regeneron just got slapped with clinical hold due to CRS for their CaR-T drug. Another interesting tidbit from the paper is gene therapy as another strategy for HIV cure, with Crispr just recently got a grant from Gates foundation for this work.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7076163/
https://www.fiercebiotech.com/biotech/regener...ral-trials